EGFR在三阴乳腺癌中的表达情况及对其预后的影响
|
摘要
三阴乳腺癌(Triple negative breast cancer, TNBC)是最近几年被提出来的一种乳腺癌亚型,专指雌激素受体(estrogen receptor, ER)、孕激素受体(progesterone receptor,PR)和人类表皮生长因子受体2(human epidermal growth factor receptor 2, HER2)都是阴性的乳腺癌。此类乳腺癌具有特殊的生物学行为和临床病理特征,表现为侵袭力强、远处转移风险高和预后差等特点。由于三阴乳腺癌的治疗目前属于摸索阶段,尚没有大规模的多中心的临床研究,还没有特有的针对三阴乳腺癌的有效治疗,因而引起医学界的广泛关注。
表皮生长因子受体(Epidermal growth factor receptor, EGFR)是一种酪氨酸激酶受体,具有酪氨酸激酶(Tyrosine kinase, TK)活性,存在于细胞膜表面,属于糖蛋白受体,它在正常细胞和恶性肿瘤细胞的生长调控方面起着重要的作用。EGFR可以通过多种机制促进细胞恶性转化,包括受体的过度表达、突变、生长因子受体自分泌环的活化以及特定的磷酸酶失活等。其中涉及肿瘤发生和进展的机制中,最常见的是EGFR的过度表达。研究发现,EGFR在多种肿瘤细胞中呈高表达,特别是在非小细胞肺癌(NSCLC)组织中,EGFR的阳性率可高达80%以上。根据EGFR对细胞生长的调控机制,一些合成药物被研制出来,如吉非替尼、西妥昔单抗、赫赛汀、范得它尼等。这些药物可以阻断EGFR介导的信号传导,从而抑制肿瘤细胞的生长、周期的延长,并抑制肿瘤对周围组织的侵袭及远处转移,促进肿瘤细胞的凋亡。经过近几年的临床实践和疗效观察,这种针对EGFR的靶向治疗在肿瘤治疗中的作用已得到了医学界的广泛肯定。
基于TNBC在治疗上的难题,以及EGFR在肿瘤治疗中的突出作用,我们把EGFR和TNBC联系起来,把EGFR在TNBC中的表达以及对TNBC的预后影响作为本论文课题研究的出发点,通过免疫组化法(IHC)、荧光原位杂交(FISH)、聚合酶链反应(PCR)等免疫学及分子生物学等实验方法,探究EGFR在TNBC的表达情况；EGFR表达与TNBC的各临床病理特征之间的联系；EGFR与TNBC预后的相关性。本实验结果显示,EGFR在TNBC中呈高表达,但扩增不明显,且未发现有突变情况；EGFR与TNBC的各病理特征之间未发现有统计学意义的分析结果；EGFR的过表达对TNBC的预后有明显的影响。因此,我们不难得出这样的结论：EGFR可做为评价TNBC预后的一个重要的指标,并可为TNBC提供一个靶向治疗的突破口。
The aim of this study was to investigate EGFR expression in TNBC, fund the relationship between the EGFR and the prognosis of TNBC patient, clarify the significance of EGFR in TNBC, give valuable information to guide further studies for the treatment of TNBC.
INTRODUCTION
EGFR
EGFR (Epidermal growth factor receptor) belongs to the HER family, and also known as HER1,is located on 7q12. EGFR is a 170-kDa transmembrane protein with tyrosine kinase activity that upon binding to its ligand. In cellular regulation mechanisms involving proliferation, differentiation and angiogenesis of cells, EGFR has a central position. Although EGFR is important in the maintenance of normal cellular function and survival, EGFR expression clearly appears to contribute to the growth and survival of tumor cells. EGFR expression has been reported to be an indicator of potential tumor progression and/or patient prognosis for such malignant tumors as esophageal cancer, gastric cancer, head and neck cancer, and ovarian cancer. A lot of studies confirm that the EGFR signal transduction pathways have been correlated with various processes that contribute to the development of malignancie. Because of the importance and the role of the EGFR pathways in cell cycle progression and tumor cell proliferation, different strategies were developed to block or downregulate EGFR. These include monoclonal antibodies to the EGFR, tyrosine kinase inhibitors, ligand-linked toxins, and antisense approaches.
TNBC
Triple-negative breast cancers (TNBC) are defined by a lack of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) expression. In 2001, Sorlie and Perou, et al. classified breast tumors into five types, i.e., the Duct A and B, Her-2 overexpression, basal-cell, and normal breast types, after an analysis of the gene expression spectrum. It was shown in the study by Carey, et al. that 80% to 90% of the TNBC cases belonged to the basal-cell type. TNBC generally occurs in younger women, less than 50 years, and is associated with a high risk of death compared with non-triple-negative tumours, regardless of disease stage at diagnosis, particularly in the first 3 years after diagnosis. On average, TNBC show a higher rate of node positivity at the time of diagnosis than other breast cancers. TNBC patients have increased frequency of distant metastasis formation, but not of local relapse. This metastatic progression is marked by early relapse with predominance of visceral and CNS metastases, and lower rate of bone metastases. In the treatment, although many trials had been done, but there is no definitive effect for TNBC all the time.
MATERIALS AND METHODS
Patients
In total,572 cases of breast cancer undergoing surgery at First Hospital of Jilin University in China from January 1,2000 to December 31,2005 were informative for ER, PR, and HER2. Of these informative cases,68(11.9%) female patients were found to be TNBCs. For 14 of 68 patients, their chemotherapy after surgery was not determined, a further 6 patients absenced integrated record about their survival data,5 of the remaining patients paraffin-embedded tissues was. insufficient to perform a series of analysis,1 patient absenced integrated record about her clinicopathological. Therefore,42 patients with TNBC were selected as research objects (TNBC group). As reference group, we select randomly 40 female patients which Immunohistochemical marked HER2 grade 3+from 572 cases (HER2 group). Because HER2 protein expression as a classic clinical feature has a important pole in the evaluation of breast cancer, we consider that it is significant to selecting HER2(3+) patients as reference group in this study.
Methods
Specimens were obtained from patients who underwent surgery. All 82 cases were subjected to Immunohistochemistry (IHC), fluorescence in situ hybridization (FISH)and reverse transcription-polymerase chain reaction (RT-PCR) to investigate EGFR gene expression, amplification and mutation. Relationship of EGFR expression and the prognosis of TNBC patient was investigated.
Statistical analysis was done using the Statistical Package for Social Sciences, Version 18.0 (SPSS).
Results
TNBC was significantly associated with age (P=0.033). No significant difference was observed regarding such tumor-related factors as tumor size, lymph node metastasis, and tumor stage, menstruation status between two groups.
Immunohistochemical study for EGFR expression
An immunohistochemical overexpression of EGFR was 34 of 82 (43.9%) breast cancer cases. Proportion of EGFR overexpression among triple negative tumors was comparatively higher than that of HER2(3+) (P=0.067),overexpression of EGFR occurring in 24 of 42 (57.1%) patients in TNBC group and 10 of 40 (25.0%) patients in HER2(3+) group. No association between EGFR overexpression and clinicopathological features was observed in two groups.
FISH analysis for EGFR gene amplification
With FISH,5 of 82 specimens could not be evaluated because of uninterpretable results of the hybridization itself. The other 77 cases could be analyzed (TNBC39, HER2(3+)38), of which 7 (9.1%) showed amplification:five triple negative tumours and two HER2 case (ER-/PR-, ER-/PR-). All cases with EGFR gene amplification by FISH showed EGFR overexpression on IHC.
PCR and Direct sequencing for EGFR Mutation
DNA extraction and polymerase chain reaction (PCR) of EGFR (exons 19 and 21) were done among the 82 patients,56 (TNBC 27, HER229) was successful. Direct sequencing analysis revealed no EGFR gene mutation in any of the successfully tested cases (n= 56).
Patients survival according to EGFR expression
The follow-up was discontinued in December 2010. After Kaplan-Meier analysis, the 5-year OS rates were 71.4%and 87.5%, the 5-year DFS rates were 57.1%and 77.5%, respectively in the TNBC and HER2 groups.
During the median follow-up period of 82 months range:(12-124 months),50 patients (61.0%) had recurrent disease (TNBC 28, HER222) and 27 patients (32.9%) died of recurrent breast cancer (TNBC 18, HER29). Of 34 patients with EGFR-overexpressing tumors,25 patients (73.5%) had recurrent disease (TNBC 19, HER2 6) and 19 patients (55.9%) died of recurrent disease during the follow-up period (TNBC 15, HER2 4). Of the remaining 48 patients with EGFR-negative tumors,25 patients (52.1%) had recurrent disease (TNBC 9, HER2 16) and 8 patients (16.7%) died of disease during the follow-up period (TNBC 3, HER2 5). Survival analysis was performed on the 82 patients with disease-free survival (DFS)and overall survival (OS), the TNBC patients were decreased when compared to those of the HER2 (3+) patients CP=0.017 for DFS, P=0.019 for OS). Both disease-free survival and overall survival of the patients having EGFR-overexpressiing tumor were decreased when compared to those of the patients with EGFR-negative tumor (P=0.027 for DFS, P=0.038 for OS). In the triple-negative subgroup, the overall survival rate of EGFR-overexpressing patients was statistically significantly lower than that of EGFR-no-overexpressing patients (P=0.018 for DFS, P=0.026 for OS). In the HER-2 subgroup, there was no statistical difference (P=0.079 for DFS, P=0.055 for OS).
Discussion
Triple negative breast carcinoma (TNBC) have a higher malignancy, more aggressive invasion, a higher proliferation rate and poorer clinical prognosis compared to other types of breast cancer. The EGFR-mediated signal transduction accounts for one of the most important pathways in carcinogenesis, and the activation of the pathway could promote such biological processes as apoptosis, cellular differentiation, tumor proliferation, invasion, adhesion, and DNA repair. In the previous literature, HER2 gene has been extensively studied in breast cancer, but the data on EGFR gene in breast cancer are limited. In recent years, more and more research about EGFR expression in breast cancer has been investigated in a variety of studies, but the research of EGFR expression in TNBC is rare. In particular, the literature concerning EGFR expression and molecular changes within TNBC tumors is sparse. The aim of this study is investigating the relationship of EGFR expression and the TNBC tumors through analysising data which obtain from immunohistochemistry and FISH and PCR.
Compared with non-TN breast cancers, TNBC have an onset at a younger age, a larger mean tumor size, higher grade, higher rate of node positivity, In our study, we only notice the age and nuclear grade have significant difference and the other tumor-related factors have no significant difference between the two groups. A principle explanation for the discrepancies reported to date concerns the various methods used to assess these statuses. Other explanations (and limitations) for our findings are that our sample size was small. Over past few years, it has been shown in studies that there was an up-regulation of the EGFR expression in the TNBC patients, and EGFR overexpression is seen in approximately 45-70%. Our research have a similar finding that the overexpression rate of EGFR was 57.14% in the TNBC group and significantly higher than in the HER2(3+) group(25.0%).In the further study, we found no correlation between EGFR expression levels and clinico-pathological data in two groups.
We further investigated the relation between EGFR overexpression by IHC and EGFR gene copy number by FISH in TNBC. In all case, only 7(9.1%) showed gene amplification, much less frequent than HER-1 overexpression 34(41.5%). In another similar study, observations were made by S Pintens et al, reporting 8.8% EGFR gene amplification and 35.1% EGFR overexpression. Comparing our FISH results with that of the former study, both showed a similar percentage of EGFR gene amplification and overexpression. These results suggest that EGFR gene amplification may not be the only mechanism of EGFR protein overexpression in TNBC; there may be other possible mechanisms and pathways that can cause EGFR overexpression. Besides gene amplification, another mechanisms can lead to aberrant EGFR expression in cancer, including receptor overexpression, abnormal mRNA slicing, mutations at gene promoter region and ligand-independent activation. Understanding this mechanism may help to locate novel molecular targets in drug discovery in treatment. Unfortunately, the mechanism of EGFR protein overexpression is poorly understood in TNBC. Notably, in our results,7 positive cases (5TNBC,2HER-2) with by FISH all showed EGFR overexpression on IHC. Because patient numbers (7cases) are too small for statistical analysis, we can't confirm that EGFR FISH-positive status correlate with EGFR overexpression in breast cancer, especially in TNBC. In more detail, we also observed 7 cases of EGFR gene amplification total with a negative ER status. Whether EGFR gene amplification associated with negative ER in breast cancer, it is necessary to further investigate.
We sought mutations in the EGFR gene in TNBCs, because these mutations were suggested to predict responses to gefitinib therapy. In our study, we investigate whether EGFR mutations (exons 19and21) could also be a feature of TNBC. But we did not find any mutations in the tested exons of TNBC and HER2 (3+) breast cancer suggesting that EGFR mutations do not contribute to receptor activation in breast cancer. However, the amount of case (56) is limited, our study cannot exclude the possible presence of a EGFR mutation in a small subset of breast cancer patients. Whether EGFR mutation exist in TNBC and could be a marker of sensitivity to antireceptor therapy, we suggest that it remains to be established in specific clinical trials.
Our researches show that disease-free survival (DFS) and overall survival (OS) in TNBC are less than that in HER-2. Moreover, our results indicate that OS and DFS rate of EGFR overexpression patients are worse than EGFR no-overexpression patients in triple-negative breast cancer group, but this observation no be fund in HER2 group. In other words, EGFR overexpression in the triple-negative breast cancer was a poor prognostic factor in our study.
Because of the development and technical progress of molecular-targeting drugs for cancer therapy, EGFR signalling has been successfully targeted in many cancer types using humanised anti-EGFR monoclonal antibodies (e.g. cetuximab) and EGFR tyrosine kinase inhibitors (e.g. gefinitib). Some literatures focused using cetuximab or gefinitib as a possible candidate for molecular-targeting on patients with TNBC expressing EGFR. Unfortunately, based on several multicenter clinical researches, the commonly-used molecular target drugs are confirmed ineffective in TNBC. For this phenomenon, Normanno N. consider, although tissues from TNBC patients often express EGFR, EGFR tyrosine kinase inhibitors have little efficacy, which partly arises through intrinsic resistance mechanisms within the tumors. B. Corkery consider, despite high levels of EGFR protein in TNBC cells, they may not be dependent on EGFR signalling for growth. Although the TNBC cells are not inherently sensitive to EGFR inhibition, several clinical trials are currently assessing that combined treatment with gefitinib and chemotherapy have a greater effect on TNBC patients. Moreover, TNBC patients have increased frequency of distant metastasis formation, but not of local relapse, indicating that these tumors are generally sensitive to irradiation.
CONCLUSION
In this study, we documented EGFR overexpression, both EGFR gene amplification and mutation, in triple negative and HER2 (3+) breast patients. We noticed a higher incidence of EGFR overexpression compared to EGFR amplification, and no EGFR gene mutation, in TNBC. However, no correlation between EGFR overexpression and clinico-pathological data. We have found that EGFR is a strong prognostic factor for relapse-free survival and overall survival for the TNBC patients. Under these treatment conditions, overexpression of EGFR could provide information concerning a poor outcome in TNBC.
表皮生长因子受体(Epidermal growth factor receptor, EGFR)是一种酪氨酸激酶受体,具有酪氨酸激酶(Tyrosine kinase, TK)活性,存在于细胞膜表面,属于糖蛋白受体,它在正常细胞和恶性肿瘤细胞的生长调控方面起着重要的作用。EGFR可以通过多种机制促进细胞恶性转化,包括受体的过度表达、突变、生长因子受体自分泌环的活化以及特定的磷酸酶失活等。其中涉及肿瘤发生和进展的机制中,最常见的是EGFR的过度表达。研究发现,EGFR在多种肿瘤细胞中呈高表达,特别是在非小细胞肺癌(NSCLC)组织中,EGFR的阳性率可高达80%以上。根据EGFR对细胞生长的调控机制,一些合成药物被研制出来,如吉非替尼、西妥昔单抗、赫赛汀、范得它尼等。这些药物可以阻断EGFR介导的信号传导,从而抑制肿瘤细胞的生长、周期的延长,并抑制肿瘤对周围组织的侵袭及远处转移,促进肿瘤细胞的凋亡。经过近几年的临床实践和疗效观察,这种针对EGFR的靶向治疗在肿瘤治疗中的作用已得到了医学界的广泛肯定。
基于TNBC在治疗上的难题,以及EGFR在肿瘤治疗中的突出作用,我们把EGFR和TNBC联系起来,把EGFR在TNBC中的表达以及对TNBC的预后影响作为本论文课题研究的出发点,通过免疫组化法(IHC)、荧光原位杂交(FISH)、聚合酶链反应(PCR)等免疫学及分子生物学等实验方法,探究EGFR在TNBC的表达情况；EGFR表达与TNBC的各临床病理特征之间的联系；EGFR与TNBC预后的相关性。本实验结果显示,EGFR在TNBC中呈高表达,但扩增不明显,且未发现有突变情况；EGFR与TNBC的各病理特征之间未发现有统计学意义的分析结果；EGFR的过表达对TNBC的预后有明显的影响。因此,我们不难得出这样的结论：EGFR可做为评价TNBC预后的一个重要的指标,并可为TNBC提供一个靶向治疗的突破口。
The aim of this study was to investigate EGFR expression in TNBC, fund the relationship between the EGFR and the prognosis of TNBC patient, clarify the significance of EGFR in TNBC, give valuable information to guide further studies for the treatment of TNBC.
INTRODUCTION
EGFR
EGFR (Epidermal growth factor receptor) belongs to the HER family, and also known as HER1,is located on 7q12. EGFR is a 170-kDa transmembrane protein with tyrosine kinase activity that upon binding to its ligand. In cellular regulation mechanisms involving proliferation, differentiation and angiogenesis of cells, EGFR has a central position. Although EGFR is important in the maintenance of normal cellular function and survival, EGFR expression clearly appears to contribute to the growth and survival of tumor cells. EGFR expression has been reported to be an indicator of potential tumor progression and/or patient prognosis for such malignant tumors as esophageal cancer, gastric cancer, head and neck cancer, and ovarian cancer. A lot of studies confirm that the EGFR signal transduction pathways have been correlated with various processes that contribute to the development of malignancie. Because of the importance and the role of the EGFR pathways in cell cycle progression and tumor cell proliferation, different strategies were developed to block or downregulate EGFR. These include monoclonal antibodies to the EGFR, tyrosine kinase inhibitors, ligand-linked toxins, and antisense approaches.
TNBC
Triple-negative breast cancers (TNBC) are defined by a lack of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) expression. In 2001, Sorlie and Perou, et al. classified breast tumors into five types, i.e., the Duct A and B, Her-2 overexpression, basal-cell, and normal breast types, after an analysis of the gene expression spectrum. It was shown in the study by Carey, et al. that 80% to 90% of the TNBC cases belonged to the basal-cell type. TNBC generally occurs in younger women, less than 50 years, and is associated with a high risk of death compared with non-triple-negative tumours, regardless of disease stage at diagnosis, particularly in the first 3 years after diagnosis. On average, TNBC show a higher rate of node positivity at the time of diagnosis than other breast cancers. TNBC patients have increased frequency of distant metastasis formation, but not of local relapse. This metastatic progression is marked by early relapse with predominance of visceral and CNS metastases, and lower rate of bone metastases. In the treatment, although many trials had been done, but there is no definitive effect for TNBC all the time.
MATERIALS AND METHODS
Patients
In total,572 cases of breast cancer undergoing surgery at First Hospital of Jilin University in China from January 1,2000 to December 31,2005 were informative for ER, PR, and HER2. Of these informative cases,68(11.9%) female patients were found to be TNBCs. For 14 of 68 patients, their chemotherapy after surgery was not determined, a further 6 patients absenced integrated record about their survival data,5 of the remaining patients paraffin-embedded tissues was. insufficient to perform a series of analysis,1 patient absenced integrated record about her clinicopathological. Therefore,42 patients with TNBC were selected as research objects (TNBC group). As reference group, we select randomly 40 female patients which Immunohistochemical marked HER2 grade 3+from 572 cases (HER2 group). Because HER2 protein expression as a classic clinical feature has a important pole in the evaluation of breast cancer, we consider that it is significant to selecting HER2(3+) patients as reference group in this study.
Methods
Specimens were obtained from patients who underwent surgery. All 82 cases were subjected to Immunohistochemistry (IHC), fluorescence in situ hybridization (FISH)and reverse transcription-polymerase chain reaction (RT-PCR) to investigate EGFR gene expression, amplification and mutation. Relationship of EGFR expression and the prognosis of TNBC patient was investigated.
Statistical analysis was done using the Statistical Package for Social Sciences, Version 18.0 (SPSS).
Results
TNBC was significantly associated with age (P=0.033). No significant difference was observed regarding such tumor-related factors as tumor size, lymph node metastasis, and tumor stage, menstruation status between two groups.
Immunohistochemical study for EGFR expression
An immunohistochemical overexpression of EGFR was 34 of 82 (43.9%) breast cancer cases. Proportion of EGFR overexpression among triple negative tumors was comparatively higher than that of HER2(3+) (P=0.067),overexpression of EGFR occurring in 24 of 42 (57.1%) patients in TNBC group and 10 of 40 (25.0%) patients in HER2(3+) group. No association between EGFR overexpression and clinicopathological features was observed in two groups.
FISH analysis for EGFR gene amplification
With FISH,5 of 82 specimens could not be evaluated because of uninterpretable results of the hybridization itself. The other 77 cases could be analyzed (TNBC39, HER2(3+)38), of which 7 (9.1%) showed amplification:five triple negative tumours and two HER2 case (ER-/PR-, ER-/PR-). All cases with EGFR gene amplification by FISH showed EGFR overexpression on IHC.
PCR and Direct sequencing for EGFR Mutation
DNA extraction and polymerase chain reaction (PCR) of EGFR (exons 19 and 21) were done among the 82 patients,56 (TNBC 27, HER229) was successful. Direct sequencing analysis revealed no EGFR gene mutation in any of the successfully tested cases (n= 56).
Patients survival according to EGFR expression
The follow-up was discontinued in December 2010. After Kaplan-Meier analysis, the 5-year OS rates were 71.4%and 87.5%, the 5-year DFS rates were 57.1%and 77.5%, respectively in the TNBC and HER2 groups.
During the median follow-up period of 82 months range:(12-124 months),50 patients (61.0%) had recurrent disease (TNBC 28, HER222) and 27 patients (32.9%) died of recurrent breast cancer (TNBC 18, HER29). Of 34 patients with EGFR-overexpressing tumors,25 patients (73.5%) had recurrent disease (TNBC 19, HER2 6) and 19 patients (55.9%) died of recurrent disease during the follow-up period (TNBC 15, HER2 4). Of the remaining 48 patients with EGFR-negative tumors,25 patients (52.1%) had recurrent disease (TNBC 9, HER2 16) and 8 patients (16.7%) died of disease during the follow-up period (TNBC 3, HER2 5). Survival analysis was performed on the 82 patients with disease-free survival (DFS)and overall survival (OS), the TNBC patients were decreased when compared to those of the HER2 (3+) patients CP=0.017 for DFS, P=0.019 for OS). Both disease-free survival and overall survival of the patients having EGFR-overexpressiing tumor were decreased when compared to those of the patients with EGFR-negative tumor (P=0.027 for DFS, P=0.038 for OS). In the triple-negative subgroup, the overall survival rate of EGFR-overexpressing patients was statistically significantly lower than that of EGFR-no-overexpressing patients (P=0.018 for DFS, P=0.026 for OS). In the HER-2 subgroup, there was no statistical difference (P=0.079 for DFS, P=0.055 for OS).
Discussion
Triple negative breast carcinoma (TNBC) have a higher malignancy, more aggressive invasion, a higher proliferation rate and poorer clinical prognosis compared to other types of breast cancer. The EGFR-mediated signal transduction accounts for one of the most important pathways in carcinogenesis, and the activation of the pathway could promote such biological processes as apoptosis, cellular differentiation, tumor proliferation, invasion, adhesion, and DNA repair. In the previous literature, HER2 gene has been extensively studied in breast cancer, but the data on EGFR gene in breast cancer are limited. In recent years, more and more research about EGFR expression in breast cancer has been investigated in a variety of studies, but the research of EGFR expression in TNBC is rare. In particular, the literature concerning EGFR expression and molecular changes within TNBC tumors is sparse. The aim of this study is investigating the relationship of EGFR expression and the TNBC tumors through analysising data which obtain from immunohistochemistry and FISH and PCR.
Compared with non-TN breast cancers, TNBC have an onset at a younger age, a larger mean tumor size, higher grade, higher rate of node positivity, In our study, we only notice the age and nuclear grade have significant difference and the other tumor-related factors have no significant difference between the two groups. A principle explanation for the discrepancies reported to date concerns the various methods used to assess these statuses. Other explanations (and limitations) for our findings are that our sample size was small. Over past few years, it has been shown in studies that there was an up-regulation of the EGFR expression in the TNBC patients, and EGFR overexpression is seen in approximately 45-70%. Our research have a similar finding that the overexpression rate of EGFR was 57.14% in the TNBC group and significantly higher than in the HER2(3+) group(25.0%).In the further study, we found no correlation between EGFR expression levels and clinico-pathological data in two groups.
We further investigated the relation between EGFR overexpression by IHC and EGFR gene copy number by FISH in TNBC. In all case, only 7(9.1%) showed gene amplification, much less frequent than HER-1 overexpression 34(41.5%). In another similar study, observations were made by S Pintens et al, reporting 8.8% EGFR gene amplification and 35.1% EGFR overexpression. Comparing our FISH results with that of the former study, both showed a similar percentage of EGFR gene amplification and overexpression. These results suggest that EGFR gene amplification may not be the only mechanism of EGFR protein overexpression in TNBC; there may be other possible mechanisms and pathways that can cause EGFR overexpression. Besides gene amplification, another mechanisms can lead to aberrant EGFR expression in cancer, including receptor overexpression, abnormal mRNA slicing, mutations at gene promoter region and ligand-independent activation. Understanding this mechanism may help to locate novel molecular targets in drug discovery in treatment. Unfortunately, the mechanism of EGFR protein overexpression is poorly understood in TNBC. Notably, in our results,7 positive cases (5TNBC,2HER-2) with by FISH all showed EGFR overexpression on IHC. Because patient numbers (7cases) are too small for statistical analysis, we can't confirm that EGFR FISH-positive status correlate with EGFR overexpression in breast cancer, especially in TNBC. In more detail, we also observed 7 cases of EGFR gene amplification total with a negative ER status. Whether EGFR gene amplification associated with negative ER in breast cancer, it is necessary to further investigate.
We sought mutations in the EGFR gene in TNBCs, because these mutations were suggested to predict responses to gefitinib therapy. In our study, we investigate whether EGFR mutations (exons 19and21) could also be a feature of TNBC. But we did not find any mutations in the tested exons of TNBC and HER2 (3+) breast cancer suggesting that EGFR mutations do not contribute to receptor activation in breast cancer. However, the amount of case (56) is limited, our study cannot exclude the possible presence of a EGFR mutation in a small subset of breast cancer patients. Whether EGFR mutation exist in TNBC and could be a marker of sensitivity to antireceptor therapy, we suggest that it remains to be established in specific clinical trials.
Our researches show that disease-free survival (DFS) and overall survival (OS) in TNBC are less than that in HER-2. Moreover, our results indicate that OS and DFS rate of EGFR overexpression patients are worse than EGFR no-overexpression patients in triple-negative breast cancer group, but this observation no be fund in HER2 group. In other words, EGFR overexpression in the triple-negative breast cancer was a poor prognostic factor in our study.
Because of the development and technical progress of molecular-targeting drugs for cancer therapy, EGFR signalling has been successfully targeted in many cancer types using humanised anti-EGFR monoclonal antibodies (e.g. cetuximab) and EGFR tyrosine kinase inhibitors (e.g. gefinitib). Some literatures focused using cetuximab or gefinitib as a possible candidate for molecular-targeting on patients with TNBC expressing EGFR. Unfortunately, based on several multicenter clinical researches, the commonly-used molecular target drugs are confirmed ineffective in TNBC. For this phenomenon, Normanno N. consider, although tissues from TNBC patients often express EGFR, EGFR tyrosine kinase inhibitors have little efficacy, which partly arises through intrinsic resistance mechanisms within the tumors. B. Corkery consider, despite high levels of EGFR protein in TNBC cells, they may not be dependent on EGFR signalling for growth. Although the TNBC cells are not inherently sensitive to EGFR inhibition, several clinical trials are currently assessing that combined treatment with gefitinib and chemotherapy have a greater effect on TNBC patients. Moreover, TNBC patients have increased frequency of distant metastasis formation, but not of local relapse, indicating that these tumors are generally sensitive to irradiation.
CONCLUSION
In this study, we documented EGFR overexpression, both EGFR gene amplification and mutation, in triple negative and HER2 (3+) breast patients. We noticed a higher incidence of EGFR overexpression compared to EGFR amplification, and no EGFR gene mutation, in TNBC. However, no correlation between EGFR overexpression and clinico-pathological data. We have found that EGFR is a strong prognostic factor for relapse-free survival and overall survival for the TNBC patients. Under these treatment conditions, overexpression of EGFR could provide information concerning a poor outcome in TNBC.
引文
[1]Jose B. Why the epidermal growth factor receptor? The rational for cancer therapy [J]. Oncllogist,2002; 7(Suppl4):2-8.
[2]Yarden Y. The EGFR family and its ligands in human cancer. Singaling mechanisms and therapeutic opportunities [J]. Eur J Cancer,2001; 37(Suppl 4):328.
[3]Jorissen RN, Walker F, Poulion N, et al. Epidermal growth factor receptor: mechanisms of activation and signaling [J]. Exp Cell Res,2003;284(1):31-53.
[4]Moghal N, Sternberg PW. Multiple positive and negative regulators of signaling by EGF-receptor[J]. Current Opinion in Cell Biology,1999; 11(2):190-196.
[5]Dowell J E, Minna J D. EGFR mutations and moleeularly targeted therapy:a new era in the treatment of lung cancer [J].Nat Clin Pract Oneol,2006; 3(4):170-171.
[6]Ruocco S, Lallemand A, Tournier JM, et al. Expression and localization of epidermal growth factor, transforming growth factor-a, and localization of their common receptor in fetal human lung development [J]. Pediatr Res,1996; 39(3):448-455.
[7]Olayioye MA, Neve RM, Lane HA, et al. The erbB signaling network:receptor heterodimerization in derelopment and cancer [J]. EMBO J,2000; 19 (13):3159-3167.
[8]Wood ER, Truesdale AT, Me Donald OB, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib):relationships among protein conformation, inhibiror off-rate and receptor activity in tumor cells [J]. Cancer Res,2004; 64(18):6652-6659.
[9]Kari C, Chan TO, Rocha de Quadros M, et al. Targeting the epidermal growth factor receptor in cancer:apoptosis take center stage [J]. Cancre Res,2003; 63(1):1-5.
[10]Lonardo F, Dragnev KH, Freemantle SJ, et al. Evidence for the epidermal growth factor receptor as a target for lung cancer prevention[J]. Clin Cancer Res,2002; 8:54-60.
[11]Wells A. The epidermal growth factor receptor (EGFR):A new target in cancer therapy [J]. Singal,2000; 1 (1):4.
[12]Cohen EE,Rosen F, Stadler WM,et al. Phase Ⅱ trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck [J]. J Clin Oncol,2003; 21(10): 1980-1987.
[13]Lorusso PM. Phase I studies of ZD1839 in patients with common solid tumors [J]. Semin Oncol,2003; 30(1Suppl 1):21-29.
[14]Quadros M R,Connelly S,Kari C,et al. EGFR-dependent downregulation of Bim in epithelial cells requires MAPK and PKC-delta activities.[J].Cancer Biol Ther,2006; 5(5): 498-504.
[15]Klapper LN, Kirschbaum MH,Sela M, et al. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors [J]. Adv Cancer Res,2000; 77: 25-79.
[16]Coley H M,Shotton C F,Ajose-Adeogun A,et al. Receptor tyrosine kinase(RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents.[J]. Biochem Pharmacol. 2006; 72(8):941-948.
[17]Yaden Y, Sliwkowski Mx, Cho Hs,et al. Untangling the ErbB signaling network[J]. Nat Rev Mol all Biol,2001; 2(2):127-137.
[18]Brideges AJ, Kim M, Robert B, et al. The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of The epidermal growth factor receptor family of tyrosine kinases [J].Curr Med Chem,1999; 6(9):825-843.
[19]Strandjord TP, Clark JG, Guralnick DE, et al. Immunolocalization of transforming growth factor alpha, epidermal growth factor (EGF), and EGF-receptor in normal and injured developing human lung [J]. Pediata Res,1995; 38(6):851-856.
[20]Hvanainen E, elimarkka LE, lenius V et al. Angiopoietin-regulated reeruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor [J]. FASEB J,2003; 17(12):1609-1621.
[21]Wingens M, Walma T, Vaningen H, et al. Structural analysis of an epidermal growth factor/transforming growth factor-alpha with unique ErbB bindings pecificity [J]. J biol Chem, 2003; 278 (40):39114-39123.
[22]Sako Y, Minoghchi S, Yanagida T. Single-molecule imaging of EGFR signalling on the surface of living cells [J].Nat Cell Biol,2000; 2(3):168-172.
[23]柏素云,王蔚林,李冠武等EGFR-STAT3信号转导通路与肿瘤[J].肿瘤防治杂志.2004,11(09)：989-991.
[24]Hackel PO,Zwiek E,Prenzel N,et al. Epidermal growth factor receptors:critical mediators of multiple receptor pathways [J]. Curr Opin Cell Biol,1999; 11:184-189.
[25]Ruan XZ, Chen XP, li RM, et al. Effects and significance of EGF and PDGF-BB on proliferation of murine bone marrow stermal stan cells in vitro [J]. Zhonghua Xiandai Yixue zazhi,2004;12(3):34-39.
[26]Nicholson RI,Gee JM,Harper ME,et al. EGFR and cancer prognosis[J]. European Journal of Cancer,2001; 37(4):9-15.
[27]Albanel J, Rojo F, Averbuch S,et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients:Histopathologic and molecular consequences of receptor inhibition [J]. J Clin Oncol,2002; 20:110-124.
[28]Jorissen RN,Walker F,Pouliot N, et al. Epidermal growth factor receptor: mechanisms of activation and signaling [J]. Exp Cell Res,2003; 284(1):31-53.
[29]Pedersen MW,Meltorn M,Damsturp L,et al. The type III epidemral growth afctor receptor mutation,biological significance and potential target for anti-cancer therapy [J]. Ann Oncol,2001,12 (6):745-760.
[30]李贤,黄中新.胚胎肺发育分化中表皮生长因子受体的表达和作用[J].解剖学研究,2000；22(2)：107-109.
[31]Spaulding DC, Spaulding BO. Epidermal growth factor receptor expression and measurement in solid tumor [J]. Semin Oncol,2002:29(5):45-54.
[32]Sato GD, Kawamoto T, Le AD, et al. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors [J]. Mol Biol Med,1983; 1:511-529.
[33]Sliwkouski Mx, Lofgren JA, Leuio GD, et al. Nonclinical studies addressing the mechanism of action of Trastuzumb (Herception) [J], Semin Oncol,1999; 26(4):60-70.
[34]Alper De Santis ML, Strornbergk, et al. Antisense suppression of epidermal growth factor receptor expression alters cellular proliferation, Cell-adhesion and tumorignicity in ovarian cancer cells [J]. Int J cancer,2000,88 (4):566-574.
[35]De laat SW, Boonstra J, Defize LH, et al. Growth factor signalling [J]. Int J Dev Biol,1999; 43 (7):681-691.
[36]Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P,Kaye FJ, Lindeman N, Boggon TJ, et al.:EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy[J]. Science 2004; 304:1497-1500.
[37]K Park, S. Han, E. Shin, H.J. Kim, J.Y. Kim. EGFR gene and protein expression in breast cancers [J]. EJSO 2007; 33:956-960.
[38]Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib[J]. Clin Cancer Res,2006; 12:5764-5769.
[39]Matsuo M, Sakurai H, Saiki I. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model [J]. Mol Cancer Ther,2003;2(6):557-561.
[40]Ciardiello F,Caputo R,Bianco R.et al. Anti-utmour effect and potentiation of cytotoxic durgs activity in human cancer cells byZD-1839(Iressa).an epidermal growth factor receptor-selective tyrosine kinase inhibitor [J].Clin Cancer Res,2000;6:2053-2063.
[41]Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy [J]. Endocr Relat Cancer,2001; 8(1):3-9.
[42]Yang XD, Jia XC,Corvalan JR, et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy [J]. Cancer Res,1999;59(6):1236-1243.
[43]Mendelsohn J. Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic [J]. Cancer Immunol Immunother,2003;52:342-346.
[44]Xu JM,Azzariti A,Severino M, et al. Characterization of Sequence-dependent synergy between ZD1839(Iressa) and oxaliplatin [J]. Biochem Pharmacol,2003; 66(4): 551-563.
[45]Xu JM, Azzariti A, Colucci G, et al. The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines [J]. Cancer Chemother Pharmacol,2003; 52(6):442-448.
[46]Perou CM,Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors[J].Nature,2000; 406:747-752.
[47]Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications [J]. Proc Natl Acad Sci USA,2001; 98:10869-10874.
[48]van't Veer LJ,Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer[J]. Nature,2002;415:530-536.
[49]van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome [J]. Am J Pathol,2002, 161:1991-1996.
[50]Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox:primary tumor chemosensitivity of breast cancer subtypes [J]. Clin Cancer Res,2007; 13(8):2329-2334.
[51]Rakha EA,EI-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer[J]. Cancer,2007; 109(1):25-32.
[52]Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer:clinical features and patterns of recurrence [J]. Clin Cancer Res,2007; 13:4429-4434.
[53]Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor(ER)-negative, progesterone receptor (PR)-negative, and HER-2 negative invasive breast cancer, the so-called triple negative phenotype:a population-based study from the California Cancer Registry [J]. Cancer,2007; 109 (9):1721-1728.
[54]Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma [J]. Mod Pathol,2006; 19:264-271.
[55]Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients:a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and end results database[J]. Cancer,2007; 110:876-884.
[56]Bryan BB, Schnitt SJ, Collins LC. Ductal carcinomain situ with basal-like phenotype:a possible precursor to invasive basal-like breast cancer [J]. Mod Pathol,2006; 19(5):617-621.
[57]Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer[J].J Clin Oncol, 2007;25(33):5287-5312.
[58]Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer[J]. J Clin Oncol,2006; 24(36):5652-5657.
[59]SusanC, Wolfgang H, Coombes RC. Triple-negative breast cancer:therapeutic options [J]. Lancet,2007; 8:235-244.
[60]Kalliopi P, Siziopikoua, Melody C, et al. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies [J]. The Breast,2007; 16:104-107.
[61]MacGrogan G, Soubeyran I, de Mascarel I, et al. Immunohistochemical detection of progester one receptors in breast invasive ductal carcinomas:a correlative study of 942 cases[J]. Appl Immunohistochemy,1996; 4(4):219-227.
[62]丁志杰,李炳仁.318例原发性乳腺癌雌、孕激素受体的表达及临床意义[J].实用肿瘤学杂志,1995；9(3)：33-34.
[63]Careia M,Rochefort H. Estrogens and breast cancer:from action mechanisms to clinical applications [J]. Ann Endocrinol (Paris),1995,56:543.
[64]高锐,杨德君,任宪卫,郝彦勇,宋燕.乳腺癌雌孕激素受体和c-erbB2癌基因表达的临床意义[J].中国实验诊断学2004；8(6)：617-618.
[65]Zellars RC, Hilsenbeck SG, Clark GM, et al. Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients [J]. Clin Oncol,2000; 18 (9):1906-1913.
[66]Hayes DF, Yamauchi H, Broadwater G, et al. Circulating HER-2/c-erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662[J[. Clin Cancer Res,2001;7 (9):2703-2711.
[67]Bern EM, foekens JA. Van Staveren IL. et al. Oncogene amplification and prognisis in breast cancer:relationship with systemic treatment [J]. Gene,1995; 159:11.
[68]A1-Ahwal MS. HER-2 positivity and correlations with other histopathologic features in breast cancer patients-hospital based study [J]. J Pak Med Assoc,2006;56 (2):65-68.
[69]Prati R, Apple SK, He.J, et al. Histopathologic characteristics predicting HER-2 /neu amplification in breast cancer [J]. Breast J,2005,11 (6):433-439.
[70]Ariga R, Zarif A, Korasick J, et al. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female beast carcinoma [J]. Breast J,2005;11(4): 278-280.
[71]Huang HJ, Neven P, Drijkoningen M, et al. Association between tumor characteristics and HER-/neu by immunohistochemistry in 1362 women with primary operable breast cancer[J]. J Clin Pathol,2005; 58 (6):611-616.
[72]Lal P, Tan LK, Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas [J]. Am J Clin Pathol, 2005; 123 (4):541-546.
[73]孙荔,徐迎春,张凤春.乳腺癌组织雌激素和孕激素受体及C-erbB-2的表达[J].上海交通大学学报医学版2007；27(6)：713-715.
[74]白云,田兴松.雌激素诱导蛋白及其影响因素在乳腺癌组织中的表达与临床意义[J].中国现代普通外科进展2007；10(2)：146-148.
[75]何萍青,何奇,郑起等C-erbB-2在乳腺癌中过度表达的临床意义[J].中国临床医学,2004；11(4)：561-562.
[76]Lund MJ, Butler EN, Bumpers HL, et al. High prevalence of triple-negative tumors in an urban cancer center[J]. Cancer,2008;113 (3):608-615.
[77]Cleator S, Heller W, Coombes RC. Triple-negative breast cancer:therapeutic options [J]. Lancet Oncol,2007; 8 (3):235-244.
[78]Eralp Y, Derin D, Ozluk Y, et al. MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer [J]. Ann Oncol,2008; 19 (4):669-674.
[79]Carey LA, Perou CM, Livasy CA, et al. Raee, breast cancer subtypes.and survival in the Carolina Breast Cancer Study[J]. JAMA,2006; 295(21):24922-24502.
[80]Yuan ZY, Wang SS, Gao Y, et al. Clinical characteristics and prognosis of triple negative breast cancer:a report of 305 cases [J]. Ai Zheng,2008;27 (6):561-565.
[81]Chen JH,Agawal G,Feig B, et al. Triple-negative breast cancer:MRI features in 29 patients [J]. Ann Oncol,2007; 18(12):2042-2043.
[82]Rakha EA, EISayed ME, Green AR, et al. Prognostic markers in triple negative breast cancer [J]. Cancer,2007,109(1):25-32.
[83]Fullbrd LG, Reis-Filho JS,Ryder K, et al. Basal-like grade Ⅲ invasive ductal carcinoma of the breast:patterns of matastasis and long term survival [J]. Breast Cancer Res, 2007; 9(1):R4.
[84]Eerola H, Vahteristo P, Sarantaus L, et al. Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families:a relative survival analysis from Finland [J]. Int J Cancer,2001;93:368-372.
[85]Tisehkowitz M, Brunet JS, Ben LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer[J]. BMC Cancer,2007; 7:134.
[86]Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification and molecular forecasting of breast cancer:Ready for clinical application? [J] Clin Oncol,2005; 23:7350.
[87]Maurer CA,Borner M, Buchler MW. Regional chemotherapy of gastro intestinal cancer[J]. Digestive Surg,1997;14(1):9-22.
[88]Garber JE, Richardson A, Harris LN, et al. Neo-adjuvant cisplatin(CDDP) in "triple-negative" breast cancer(BC). Program and abstracts of the 29th Annual San Antonio Breast Cancer Symposium, December 14-17,2006; San Antonio, Texas, Abstract 3074.
[89]Rody A, Karn T, Solbach C, et al. The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neo-adjuvant chemotherapy with docetaxel doxorubicin and cyclophosphamide within the GEPARTRIO trial[J]. Breast, 2007; 16:235-240.
[90]Kassam F, Enright K, Dent R, et al. Survival outcomes for patients with metastatic triple-negative breast cancer implications for clinical practice and trial design[J]. Clin Breast Cancer,2009;9:29-33.
[91]李威,王培忠.乳腺癌患者生存质量的测量量表及研究进展[J].中国肿瘤临床,2006；33(19)：1132-1135.
[92]Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer [J]. Semin Onco,12006,33(4):369-385.
[93]Siziopikou KP, Ariga R, Proussaloglou KE, et al. The challenging estrogen receptor-negative/progesterone receptor-negative/HER-2-negative patient:A promising candidate for epidermal growth factor receptor-targeted therapy? [J] Breast J,2006; 12(4): 360-362.
[94]Josep Tabernero. The Role of VEGF and EGFR Inhibition:Implications for Combining Anti-VEGF and Anti-EGFR Agents[J]. Molecular Cancer Research5,2007;3(1),203-220.
[95]Boukhalfa-Heniche FZ,Hernandez B,Gaillard S, et al. Complex formation and vectorization of a phosphorothioate oligonucleotide with an amphipathic leueine-and lysine-rich peptide:study at molecular and cellular levels [J].Biopolymers.2004; 73(6): 727-734.
[96]Bulteau L, Raymond G, Cognard C. Antisense oligonucleotides against 'cardiac' and 'skeletal',DHP-receptors reveal a dual role for the 'skeletal' isoform in EC coupling of skeletal muscle cells in primary culture[J]. J Cell Sci.1998Aug; 111 (Pt 15):2149-2158.
[97]Chrysogelos SA, Dickson RB. EGF receptor expression,regulation, and function in breast cancer[J]. Breast Cancer Res Treat,1994;29(1):29.
[98]Hendriks BS, Wiley HS, Lauffenburger D. HER2-mediated effects on EGFR endosomal sorting:analysis of biophysical mechanisms[J].BioPhys J.2003;85(4):2732-2745.
[99]Al Moustafa AE, Foulkes WD,Benlimame N, et al. E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal ora epithelial cells[J].Oncogene.2004;23(2):350-358.
[100]Nicholson RI, Hutcheson IR, Knowlden JM, et al. Nonendocrine pathways and endocrine resistance:Observations with anti-estrogens and signal transduction inhibitors in combination [J]. Clin Cancer Res,2004;10 (1):346.
[101]Colleoni M, Gelber S, Goldhirsch A, et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer [J]. J Clin Oncol, 2006;24(9):1332-1341.
[102]Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes,and survival in the Carolina Breast Cancer Study[J].JAMA,2006; 295(21):2492-2502.
[103]Sara M, Bando Y, Takahashi M, et al. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer[J]. J Surg Oncol,2008; 97(1):30-34.
[104]Km MJ, Ro JY, Ahn SH, et al. Clinicopathologic significance of the basal-like subtype of breast cancer:A comparison with hormone receptor and Her2/neu over-expressing phenotypes[J]. Hum Pathol,2006; 37(9):1217-1226.
[105]袁中玉,王树森,高岩,等.305例三阴乳腺癌患者的临床特征及预后因素分析[J].癌症,2008；27(6)：561-565.
[106]关印,徐冰河.三阴性乳腺癌的临床病理特征及预后分析[J].中华肿瘤杂志,2008；30(3)：196-199.
[107]Kaplan HG, Malmgren JA. Impact of triple negative phenotype on breast cancer prognosis[J]. Breast J,2008; 14(5):456-463.
[108]Yadren Y. The EGFR family and its ligands in human cancer. Signaling mechanisms and therapeutic opportunities [J]. Eur J Cancer,2001;37(Suppl4):s3-8.
[109]Capdevila J, Elez E, Macarulla T, Ramos FJ, Ruiz-Echarri M, Tabernero J. Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment [J]. Cancer Treat Rev.2009;35:354-363.
[110]Jost M, Huggett TM, Kari C,et al. Epidermal growth factor receptor-Dependent control of keratinocyte survival and Bcl-xL expression through a MEK-dependent pathway [J]. J Biol Chem,2001; 276(9):6320-6326.
[111]Gilmore AP,Valentijn AJ,Wang P,et al. Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor [J]. J Biol Chem,2002; 277(31):27643-27650.
[112]Rakha EA, EI-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer [J]. Cancer,2007,109:25.
[113]Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinica characterization of the basal-like subtype of invasive breast carcinoma [J]. Clin Cancer Res, 2004; 10(16):5367-5374.
[114]Collins LC, Martyniak AJ, Kandel MJ, et al. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Am J Surg Pathol. [Epub ahead of print].)
[115]邓再兴,俞文菊,朱凯,等.乳腺癌组织cKS/6与EGFR表达及其临床意义的研究[J].中华肿瘤防治杂志,2008；15(19)：2477-1480.
[116]Cheang MC, Voduc D, Bajdik C, et al:Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype [J]. Clin Cancer Res 2008; 14:1368-1376.
[117]Nogi H, Kobayashi T, Suzuki M, Tabei I, Kawase K, Toriumi Y, et al. EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer [J]. Oncol Rep.2009; 21:413-417.
[118]Corkery B, Crown J, Clynes M, O'Donovan N. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer [J]. Ann Oncol. 2009;20:862-867.
[119]Scagiiotti GV, Selvaggi G, Novello S, et al. The biology of epidermal growth factor receptor in lung cancer [J]. Clin Cancer Res2004; 10:4227s-4232s.
[120]Reissmnna PT, Koga H, Figlin RA, et al. Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. Lung Cancer Study Group [J]. J Cancer Res Clin Onocl 1999; 125:61-70.
[121]Wang X, Jones TD, Zhang S et al. Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, andandrogen receptor in phyllodes tumor of the prostate [J]. Mod Pathol,2007; 20:175-182.
[122]Semir Vranic MD, Snjezana Frkovic-Grazio MD, et al. Adenoid cystic carcinomas of the breast have low Topo Hot expression but frequently overexpress EGFR protein without EGFR gene amplification [J]. Human Pathology,2010; 41:1617-1623.
[123]S Pintens, P Neven, M Drijkoningen, et al. Triple negative breast cancer:a study from the point of view of basal CK5/6 and HER-1 [J]. J Clin Pathol,2009; 62:624-628.
[124]Sasaki H, Endo K, Konishi A, Takada M, Kawahara M, Iuchi K, Matsumura A, Okumura M, Tanaka H, Kawaguchi T, et al.:EGFR Mutation status in Japanese lung cancer patients:genotyping analysis using LightCycler [J]. Clin Cancer Res 2005;11:2924-2929.
[125]Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. [J]. The New England journal of medicine,2004; 350(21):2129-2139.
[126]TAMURA K, OKAMOTO I, KASHII T, et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations:results of the West Japan Thoracic Oncology Group trial (WJTOG0403) [J]. British journal of cancer,2008;98:907-914.
[127]Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S,Chella A, et al. EGFR mutations in non-small-cell lung cancer:analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment [J]. J Clin Oncol,2005; 23:857-865.
[128]Bhargava R, Gerald WL, Li AR, Pan Q, Lai P, Ladanyi M, Chen B:EGFR gene amplification in breast cancer:correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.Mod Pathol 2005 in press.
[129]Lee JW, Soung YH, Kim SY, Park WS, Nam SW, Lee JY, Yoo NJ,Lee SH: Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer [J]. Int J Cancer 2005;113:510-511.
[130]Therasse P, Arbuck SG, Eisenhauer EA, et al:New guidelines to evaluate the response to treatment in solid rumors. EuropeanOrganization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada [J]. J Natl Cancer Inst 2000;92:205-216.
[131]Weber F, Fukino K, Sawada T, Williams N, Sweet K, Brena RM, Plass C, Caldes T, Mutter GL, Villalona-Calero MA, et al.:Variability in organ-specific EGFR mutational spectra in rumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors [J]. Br J Cancer 2005;92:1922-1926.
[132]Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and ceruximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J]. N Engl J Med 2004; 351(4):337-345.
[133]Ana Bosch, Pilar Eroles, et al.Triple-negative breast cancer:Molecular features, pathogenesis, treatment and current lines of research [J]. Cancer Treatment Reviews,2010;36: 206-215.
[134]Irvin WJ Jr, Carey LA. What is triple-negative breast cancer [J]. Eur J Cancer, 2008; 44:2799-2805.
[135]Normanno N, Luca AD, Maiello MR, Campiglio M, Napolitano M, Mancino M, Carotenuto A, Viglietto G, Menard S. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib [J]. J Cell Physiol,2006; 207:420-427.
[136]B. Corkery, J. Crownl, M. Clynes, N. O'Donovan. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer[J]. Annals of Oncology 2009:20:862-867.
[137]Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer:a critical review [J]. J Clin Oncol 2008;26(15):2568-81.
[138]Janneke E. Jaspers, Sven Rottenberg, Jos Jonkers. Therapeutic options for triple-negative breast cancers with defective homologous recombination[J]. Biochimica et Biophysica Acta,2009; 1796:266-280.
[2]Yarden Y. The EGFR family and its ligands in human cancer. Singaling mechanisms and therapeutic opportunities [J]. Eur J Cancer,2001; 37(Suppl 4):328.
[3]Jorissen RN, Walker F, Poulion N, et al. Epidermal growth factor receptor: mechanisms of activation and signaling [J]. Exp Cell Res,2003;284(1):31-53.
[4]Moghal N, Sternberg PW. Multiple positive and negative regulators of signaling by EGF-receptor[J]. Current Opinion in Cell Biology,1999; 11(2):190-196.
[5]Dowell J E, Minna J D. EGFR mutations and moleeularly targeted therapy:a new era in the treatment of lung cancer [J].Nat Clin Pract Oneol,2006; 3(4):170-171.
[6]Ruocco S, Lallemand A, Tournier JM, et al. Expression and localization of epidermal growth factor, transforming growth factor-a, and localization of their common receptor in fetal human lung development [J]. Pediatr Res,1996; 39(3):448-455.
[7]Olayioye MA, Neve RM, Lane HA, et al. The erbB signaling network:receptor heterodimerization in derelopment and cancer [J]. EMBO J,2000; 19 (13):3159-3167.
[8]Wood ER, Truesdale AT, Me Donald OB, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib):relationships among protein conformation, inhibiror off-rate and receptor activity in tumor cells [J]. Cancer Res,2004; 64(18):6652-6659.
[9]Kari C, Chan TO, Rocha de Quadros M, et al. Targeting the epidermal growth factor receptor in cancer:apoptosis take center stage [J]. Cancre Res,2003; 63(1):1-5.
[10]Lonardo F, Dragnev KH, Freemantle SJ, et al. Evidence for the epidermal growth factor receptor as a target for lung cancer prevention[J]. Clin Cancer Res,2002; 8:54-60.
[11]Wells A. The epidermal growth factor receptor (EGFR):A new target in cancer therapy [J]. Singal,2000; 1 (1):4.
[12]Cohen EE,Rosen F, Stadler WM,et al. Phase Ⅱ trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck [J]. J Clin Oncol,2003; 21(10): 1980-1987.
[13]Lorusso PM. Phase I studies of ZD1839 in patients with common solid tumors [J]. Semin Oncol,2003; 30(1Suppl 1):21-29.
[14]Quadros M R,Connelly S,Kari C,et al. EGFR-dependent downregulation of Bim in epithelial cells requires MAPK and PKC-delta activities.[J].Cancer Biol Ther,2006; 5(5): 498-504.
[15]Klapper LN, Kirschbaum MH,Sela M, et al. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors [J]. Adv Cancer Res,2000; 77: 25-79.
[16]Coley H M,Shotton C F,Ajose-Adeogun A,et al. Receptor tyrosine kinase(RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents.[J]. Biochem Pharmacol. 2006; 72(8):941-948.
[17]Yaden Y, Sliwkowski Mx, Cho Hs,et al. Untangling the ErbB signaling network[J]. Nat Rev Mol all Biol,2001; 2(2):127-137.
[18]Brideges AJ, Kim M, Robert B, et al. The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of The epidermal growth factor receptor family of tyrosine kinases [J].Curr Med Chem,1999; 6(9):825-843.
[19]Strandjord TP, Clark JG, Guralnick DE, et al. Immunolocalization of transforming growth factor alpha, epidermal growth factor (EGF), and EGF-receptor in normal and injured developing human lung [J]. Pediata Res,1995; 38(6):851-856.
[20]Hvanainen E, elimarkka LE, lenius V et al. Angiopoietin-regulated reeruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor [J]. FASEB J,2003; 17(12):1609-1621.
[21]Wingens M, Walma T, Vaningen H, et al. Structural analysis of an epidermal growth factor/transforming growth factor-alpha with unique ErbB bindings pecificity [J]. J biol Chem, 2003; 278 (40):39114-39123.
[22]Sako Y, Minoghchi S, Yanagida T. Single-molecule imaging of EGFR signalling on the surface of living cells [J].Nat Cell Biol,2000; 2(3):168-172.
[23]柏素云,王蔚林,李冠武等EGFR-STAT3信号转导通路与肿瘤[J].肿瘤防治杂志.2004,11(09)：989-991.
[24]Hackel PO,Zwiek E,Prenzel N,et al. Epidermal growth factor receptors:critical mediators of multiple receptor pathways [J]. Curr Opin Cell Biol,1999; 11:184-189.
[25]Ruan XZ, Chen XP, li RM, et al. Effects and significance of EGF and PDGF-BB on proliferation of murine bone marrow stermal stan cells in vitro [J]. Zhonghua Xiandai Yixue zazhi,2004;12(3):34-39.
[26]Nicholson RI,Gee JM,Harper ME,et al. EGFR and cancer prognosis[J]. European Journal of Cancer,2001; 37(4):9-15.
[27]Albanel J, Rojo F, Averbuch S,et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients:Histopathologic and molecular consequences of receptor inhibition [J]. J Clin Oncol,2002; 20:110-124.
[28]Jorissen RN,Walker F,Pouliot N, et al. Epidermal growth factor receptor: mechanisms of activation and signaling [J]. Exp Cell Res,2003; 284(1):31-53.
[29]Pedersen MW,Meltorn M,Damsturp L,et al. The type III epidemral growth afctor receptor mutation,biological significance and potential target for anti-cancer therapy [J]. Ann Oncol,2001,12 (6):745-760.
[30]李贤,黄中新.胚胎肺发育分化中表皮生长因子受体的表达和作用[J].解剖学研究,2000；22(2)：107-109.
[31]Spaulding DC, Spaulding BO. Epidermal growth factor receptor expression and measurement in solid tumor [J]. Semin Oncol,2002:29(5):45-54.
[32]Sato GD, Kawamoto T, Le AD, et al. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors [J]. Mol Biol Med,1983; 1:511-529.
[33]Sliwkouski Mx, Lofgren JA, Leuio GD, et al. Nonclinical studies addressing the mechanism of action of Trastuzumb (Herception) [J], Semin Oncol,1999; 26(4):60-70.
[34]Alper De Santis ML, Strornbergk, et al. Antisense suppression of epidermal growth factor receptor expression alters cellular proliferation, Cell-adhesion and tumorignicity in ovarian cancer cells [J]. Int J cancer,2000,88 (4):566-574.
[35]De laat SW, Boonstra J, Defize LH, et al. Growth factor signalling [J]. Int J Dev Biol,1999; 43 (7):681-691.
[36]Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P,Kaye FJ, Lindeman N, Boggon TJ, et al.:EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy[J]. Science 2004; 304:1497-1500.
[37]K Park, S. Han, E. Shin, H.J. Kim, J.Y. Kim. EGFR gene and protein expression in breast cancers [J]. EJSO 2007; 33:956-960.
[38]Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib[J]. Clin Cancer Res,2006; 12:5764-5769.
[39]Matsuo M, Sakurai H, Saiki I. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model [J]. Mol Cancer Ther,2003;2(6):557-561.
[40]Ciardiello F,Caputo R,Bianco R.et al. Anti-utmour effect and potentiation of cytotoxic durgs activity in human cancer cells byZD-1839(Iressa).an epidermal growth factor receptor-selective tyrosine kinase inhibitor [J].Clin Cancer Res,2000;6:2053-2063.
[41]Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy [J]. Endocr Relat Cancer,2001; 8(1):3-9.
[42]Yang XD, Jia XC,Corvalan JR, et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy [J]. Cancer Res,1999;59(6):1236-1243.
[43]Mendelsohn J. Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic [J]. Cancer Immunol Immunother,2003;52:342-346.
[44]Xu JM,Azzariti A,Severino M, et al. Characterization of Sequence-dependent synergy between ZD1839(Iressa) and oxaliplatin [J]. Biochem Pharmacol,2003; 66(4): 551-563.
[45]Xu JM, Azzariti A, Colucci G, et al. The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines [J]. Cancer Chemother Pharmacol,2003; 52(6):442-448.
[46]Perou CM,Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors[J].Nature,2000; 406:747-752.
[47]Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications [J]. Proc Natl Acad Sci USA,2001; 98:10869-10874.
[48]van't Veer LJ,Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer[J]. Nature,2002;415:530-536.
[49]van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome [J]. Am J Pathol,2002, 161:1991-1996.
[50]Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox:primary tumor chemosensitivity of breast cancer subtypes [J]. Clin Cancer Res,2007; 13(8):2329-2334.
[51]Rakha EA,EI-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer[J]. Cancer,2007; 109(1):25-32.
[52]Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer:clinical features and patterns of recurrence [J]. Clin Cancer Res,2007; 13:4429-4434.
[53]Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor(ER)-negative, progesterone receptor (PR)-negative, and HER-2 negative invasive breast cancer, the so-called triple negative phenotype:a population-based study from the California Cancer Registry [J]. Cancer,2007; 109 (9):1721-1728.
[54]Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma [J]. Mod Pathol,2006; 19:264-271.
[55]Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients:a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and end results database[J]. Cancer,2007; 110:876-884.
[56]Bryan BB, Schnitt SJ, Collins LC. Ductal carcinomain situ with basal-like phenotype:a possible precursor to invasive basal-like breast cancer [J]. Mod Pathol,2006; 19(5):617-621.
[57]Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer[J].J Clin Oncol, 2007;25(33):5287-5312.
[58]Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer[J]. J Clin Oncol,2006; 24(36):5652-5657.
[59]SusanC, Wolfgang H, Coombes RC. Triple-negative breast cancer:therapeutic options [J]. Lancet,2007; 8:235-244.
[60]Kalliopi P, Siziopikoua, Melody C, et al. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies [J]. The Breast,2007; 16:104-107.
[61]MacGrogan G, Soubeyran I, de Mascarel I, et al. Immunohistochemical detection of progester one receptors in breast invasive ductal carcinomas:a correlative study of 942 cases[J]. Appl Immunohistochemy,1996; 4(4):219-227.
[62]丁志杰,李炳仁.318例原发性乳腺癌雌、孕激素受体的表达及临床意义[J].实用肿瘤学杂志,1995；9(3)：33-34.
[63]Careia M,Rochefort H. Estrogens and breast cancer:from action mechanisms to clinical applications [J]. Ann Endocrinol (Paris),1995,56:543.
[64]高锐,杨德君,任宪卫,郝彦勇,宋燕.乳腺癌雌孕激素受体和c-erbB2癌基因表达的临床意义[J].中国实验诊断学2004；8(6)：617-618.
[65]Zellars RC, Hilsenbeck SG, Clark GM, et al. Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients [J]. Clin Oncol,2000; 18 (9):1906-1913.
[66]Hayes DF, Yamauchi H, Broadwater G, et al. Circulating HER-2/c-erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662[J[. Clin Cancer Res,2001;7 (9):2703-2711.
[67]Bern EM, foekens JA. Van Staveren IL. et al. Oncogene amplification and prognisis in breast cancer:relationship with systemic treatment [J]. Gene,1995; 159:11.
[68]A1-Ahwal MS. HER-2 positivity and correlations with other histopathologic features in breast cancer patients-hospital based study [J]. J Pak Med Assoc,2006;56 (2):65-68.
[69]Prati R, Apple SK, He.J, et al. Histopathologic characteristics predicting HER-2 /neu amplification in breast cancer [J]. Breast J,2005,11 (6):433-439.
[70]Ariga R, Zarif A, Korasick J, et al. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female beast carcinoma [J]. Breast J,2005;11(4): 278-280.
[71]Huang HJ, Neven P, Drijkoningen M, et al. Association between tumor characteristics and HER-/neu by immunohistochemistry in 1362 women with primary operable breast cancer[J]. J Clin Pathol,2005; 58 (6):611-616.
[72]Lal P, Tan LK, Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas [J]. Am J Clin Pathol, 2005; 123 (4):541-546.
[73]孙荔,徐迎春,张凤春.乳腺癌组织雌激素和孕激素受体及C-erbB-2的表达[J].上海交通大学学报医学版2007；27(6)：713-715.
[74]白云,田兴松.雌激素诱导蛋白及其影响因素在乳腺癌组织中的表达与临床意义[J].中国现代普通外科进展2007；10(2)：146-148.
[75]何萍青,何奇,郑起等C-erbB-2在乳腺癌中过度表达的临床意义[J].中国临床医学,2004；11(4)：561-562.
[76]Lund MJ, Butler EN, Bumpers HL, et al. High prevalence of triple-negative tumors in an urban cancer center[J]. Cancer,2008;113 (3):608-615.
[77]Cleator S, Heller W, Coombes RC. Triple-negative breast cancer:therapeutic options [J]. Lancet Oncol,2007; 8 (3):235-244.
[78]Eralp Y, Derin D, Ozluk Y, et al. MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer [J]. Ann Oncol,2008; 19 (4):669-674.
[79]Carey LA, Perou CM, Livasy CA, et al. Raee, breast cancer subtypes.and survival in the Carolina Breast Cancer Study[J]. JAMA,2006; 295(21):24922-24502.
[80]Yuan ZY, Wang SS, Gao Y, et al. Clinical characteristics and prognosis of triple negative breast cancer:a report of 305 cases [J]. Ai Zheng,2008;27 (6):561-565.
[81]Chen JH,Agawal G,Feig B, et al. Triple-negative breast cancer:MRI features in 29 patients [J]. Ann Oncol,2007; 18(12):2042-2043.
[82]Rakha EA, EISayed ME, Green AR, et al. Prognostic markers in triple negative breast cancer [J]. Cancer,2007,109(1):25-32.
[83]Fullbrd LG, Reis-Filho JS,Ryder K, et al. Basal-like grade Ⅲ invasive ductal carcinoma of the breast:patterns of matastasis and long term survival [J]. Breast Cancer Res, 2007; 9(1):R4.
[84]Eerola H, Vahteristo P, Sarantaus L, et al. Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families:a relative survival analysis from Finland [J]. Int J Cancer,2001;93:368-372.
[85]Tisehkowitz M, Brunet JS, Ben LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer[J]. BMC Cancer,2007; 7:134.
[86]Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification and molecular forecasting of breast cancer:Ready for clinical application? [J] Clin Oncol,2005; 23:7350.
[87]Maurer CA,Borner M, Buchler MW. Regional chemotherapy of gastro intestinal cancer[J]. Digestive Surg,1997;14(1):9-22.
[88]Garber JE, Richardson A, Harris LN, et al. Neo-adjuvant cisplatin(CDDP) in "triple-negative" breast cancer(BC). Program and abstracts of the 29th Annual San Antonio Breast Cancer Symposium, December 14-17,2006; San Antonio, Texas, Abstract 3074.
[89]Rody A, Karn T, Solbach C, et al. The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neo-adjuvant chemotherapy with docetaxel doxorubicin and cyclophosphamide within the GEPARTRIO trial[J]. Breast, 2007; 16:235-240.
[90]Kassam F, Enright K, Dent R, et al. Survival outcomes for patients with metastatic triple-negative breast cancer implications for clinical practice and trial design[J]. Clin Breast Cancer,2009;9:29-33.
[91]李威,王培忠.乳腺癌患者生存质量的测量量表及研究进展[J].中国肿瘤临床,2006；33(19)：1132-1135.
[92]Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer [J]. Semin Onco,12006,33(4):369-385.
[93]Siziopikou KP, Ariga R, Proussaloglou KE, et al. The challenging estrogen receptor-negative/progesterone receptor-negative/HER-2-negative patient:A promising candidate for epidermal growth factor receptor-targeted therapy? [J] Breast J,2006; 12(4): 360-362.
[94]Josep Tabernero. The Role of VEGF and EGFR Inhibition:Implications for Combining Anti-VEGF and Anti-EGFR Agents[J]. Molecular Cancer Research5,2007;3(1),203-220.
[95]Boukhalfa-Heniche FZ,Hernandez B,Gaillard S, et al. Complex formation and vectorization of a phosphorothioate oligonucleotide with an amphipathic leueine-and lysine-rich peptide:study at molecular and cellular levels [J].Biopolymers.2004; 73(6): 727-734.
[96]Bulteau L, Raymond G, Cognard C. Antisense oligonucleotides against 'cardiac' and 'skeletal',DHP-receptors reveal a dual role for the 'skeletal' isoform in EC coupling of skeletal muscle cells in primary culture[J]. J Cell Sci.1998Aug; 111 (Pt 15):2149-2158.
[97]Chrysogelos SA, Dickson RB. EGF receptor expression,regulation, and function in breast cancer[J]. Breast Cancer Res Treat,1994;29(1):29.
[98]Hendriks BS, Wiley HS, Lauffenburger D. HER2-mediated effects on EGFR endosomal sorting:analysis of biophysical mechanisms[J].BioPhys J.2003;85(4):2732-2745.
[99]Al Moustafa AE, Foulkes WD,Benlimame N, et al. E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal ora epithelial cells[J].Oncogene.2004;23(2):350-358.
[100]Nicholson RI, Hutcheson IR, Knowlden JM, et al. Nonendocrine pathways and endocrine resistance:Observations with anti-estrogens and signal transduction inhibitors in combination [J]. Clin Cancer Res,2004;10 (1):346.
[101]Colleoni M, Gelber S, Goldhirsch A, et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer [J]. J Clin Oncol, 2006;24(9):1332-1341.
[102]Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes,and survival in the Carolina Breast Cancer Study[J].JAMA,2006; 295(21):2492-2502.
[103]Sara M, Bando Y, Takahashi M, et al. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer[J]. J Surg Oncol,2008; 97(1):30-34.
[104]Km MJ, Ro JY, Ahn SH, et al. Clinicopathologic significance of the basal-like subtype of breast cancer:A comparison with hormone receptor and Her2/neu over-expressing phenotypes[J]. Hum Pathol,2006; 37(9):1217-1226.
[105]袁中玉,王树森,高岩,等.305例三阴乳腺癌患者的临床特征及预后因素分析[J].癌症,2008；27(6)：561-565.
[106]关印,徐冰河.三阴性乳腺癌的临床病理特征及预后分析[J].中华肿瘤杂志,2008；30(3)：196-199.
[107]Kaplan HG, Malmgren JA. Impact of triple negative phenotype on breast cancer prognosis[J]. Breast J,2008; 14(5):456-463.
[108]Yadren Y. The EGFR family and its ligands in human cancer. Signaling mechanisms and therapeutic opportunities [J]. Eur J Cancer,2001;37(Suppl4):s3-8.
[109]Capdevila J, Elez E, Macarulla T, Ramos FJ, Ruiz-Echarri M, Tabernero J. Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment [J]. Cancer Treat Rev.2009;35:354-363.
[110]Jost M, Huggett TM, Kari C,et al. Epidermal growth factor receptor-Dependent control of keratinocyte survival and Bcl-xL expression through a MEK-dependent pathway [J]. J Biol Chem,2001; 276(9):6320-6326.
[111]Gilmore AP,Valentijn AJ,Wang P,et al. Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor [J]. J Biol Chem,2002; 277(31):27643-27650.
[112]Rakha EA, EI-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer [J]. Cancer,2007,109:25.
[113]Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinica characterization of the basal-like subtype of invasive breast carcinoma [J]. Clin Cancer Res, 2004; 10(16):5367-5374.
[114]Collins LC, Martyniak AJ, Kandel MJ, et al. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Am J Surg Pathol. [Epub ahead of print].)
[115]邓再兴,俞文菊,朱凯,等.乳腺癌组织cKS/6与EGFR表达及其临床意义的研究[J].中华肿瘤防治杂志,2008；15(19)：2477-1480.
[116]Cheang MC, Voduc D, Bajdik C, et al:Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype [J]. Clin Cancer Res 2008; 14:1368-1376.
[117]Nogi H, Kobayashi T, Suzuki M, Tabei I, Kawase K, Toriumi Y, et al. EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer [J]. Oncol Rep.2009; 21:413-417.
[118]Corkery B, Crown J, Clynes M, O'Donovan N. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer [J]. Ann Oncol. 2009;20:862-867.
[119]Scagiiotti GV, Selvaggi G, Novello S, et al. The biology of epidermal growth factor receptor in lung cancer [J]. Clin Cancer Res2004; 10:4227s-4232s.
[120]Reissmnna PT, Koga H, Figlin RA, et al. Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. Lung Cancer Study Group [J]. J Cancer Res Clin Onocl 1999; 125:61-70.
[121]Wang X, Jones TD, Zhang S et al. Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, andandrogen receptor in phyllodes tumor of the prostate [J]. Mod Pathol,2007; 20:175-182.
[122]Semir Vranic MD, Snjezana Frkovic-Grazio MD, et al. Adenoid cystic carcinomas of the breast have low Topo Hot expression but frequently overexpress EGFR protein without EGFR gene amplification [J]. Human Pathology,2010; 41:1617-1623.
[123]S Pintens, P Neven, M Drijkoningen, et al. Triple negative breast cancer:a study from the point of view of basal CK5/6 and HER-1 [J]. J Clin Pathol,2009; 62:624-628.
[124]Sasaki H, Endo K, Konishi A, Takada M, Kawahara M, Iuchi K, Matsumura A, Okumura M, Tanaka H, Kawaguchi T, et al.:EGFR Mutation status in Japanese lung cancer patients:genotyping analysis using LightCycler [J]. Clin Cancer Res 2005;11:2924-2929.
[125]Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. [J]. The New England journal of medicine,2004; 350(21):2129-2139.
[126]TAMURA K, OKAMOTO I, KASHII T, et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations:results of the West Japan Thoracic Oncology Group trial (WJTOG0403) [J]. British journal of cancer,2008;98:907-914.
[127]Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S,Chella A, et al. EGFR mutations in non-small-cell lung cancer:analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment [J]. J Clin Oncol,2005; 23:857-865.
[128]Bhargava R, Gerald WL, Li AR, Pan Q, Lai P, Ladanyi M, Chen B:EGFR gene amplification in breast cancer:correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.Mod Pathol 2005 in press.
[129]Lee JW, Soung YH, Kim SY, Park WS, Nam SW, Lee JY, Yoo NJ,Lee SH: Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer [J]. Int J Cancer 2005;113:510-511.
[130]Therasse P, Arbuck SG, Eisenhauer EA, et al:New guidelines to evaluate the response to treatment in solid rumors. EuropeanOrganization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada [J]. J Natl Cancer Inst 2000;92:205-216.
[131]Weber F, Fukino K, Sawada T, Williams N, Sweet K, Brena RM, Plass C, Caldes T, Mutter GL, Villalona-Calero MA, et al.:Variability in organ-specific EGFR mutational spectra in rumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors [J]. Br J Cancer 2005;92:1922-1926.
[132]Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and ceruximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J]. N Engl J Med 2004; 351(4):337-345.
[133]Ana Bosch, Pilar Eroles, et al.Triple-negative breast cancer:Molecular features, pathogenesis, treatment and current lines of research [J]. Cancer Treatment Reviews,2010;36: 206-215.
[134]Irvin WJ Jr, Carey LA. What is triple-negative breast cancer [J]. Eur J Cancer, 2008; 44:2799-2805.
[135]Normanno N, Luca AD, Maiello MR, Campiglio M, Napolitano M, Mancino M, Carotenuto A, Viglietto G, Menard S. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib [J]. J Cell Physiol,2006; 207:420-427.
[136]B. Corkery, J. Crownl, M. Clynes, N. O'Donovan. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer[J]. Annals of Oncology 2009:20:862-867.
[137]Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer:a critical review [J]. J Clin Oncol 2008;26(15):2568-81.
[138]Janneke E. Jaspers, Sven Rottenberg, Jos Jonkers. Therapeutic options for triple-negative breast cancers with defective homologous recombination[J]. Biochimica et Biophysica Acta,2009; 1796:266-280.